International FOP Association

Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting

Retrieved on: 
Tuesday, August 25, 2020
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Health, Chemical compounds, Rare diseases, Palovarotene, Pyrazoles, Retinoids, Fibrodysplasia ossificans progressiva, FOP, Fibrodysplasia, Clinical trial, International FOP Association, the FOP clinical program, palovarotene, fibrodysplasia ossificans progressiva (FOP), Ipsen

Dosing of palovarotene in the MOVE clinical trial was paused when futility criteria were met at a pre-specified interim analysis.

Key Points: 
  • Dosing of palovarotene in the MOVE clinical trial was paused when futility criteria were met at a pre-specified interim analysis.
  • We are pleased to present the third interim analysis results of the Phase III MOVE trial in FOP, evaluating Ipsens oral investigational therapy palovarotene, to the global community at the ASBMR annual meeting, said Jim Roach, M.D., Senior Vice President and Global Head of Rare Diseases Therapeutic Area at Ipsen.
  • Dosing for eligible study patients 14 years of age has resumed across the Phase II and Phase III programs for palovarotene in FOP.
  • Palovarotene (PVO) for fibrodysplasia ossificans progressiva (FOP): Data from the phase III MOVE trial.

Keros Therapeutics to be Featured on The Balancing Act's "Behind the Mystery" Rare Disease Series

Retrieved on: 
Monday, August 10, 2020
International FOP Association, Restoration comedy, FOP, Keros, FOP, Islands, Landforms

Keros is honored to have the opportunity to bring awareness of FOP to a wider audience.

Key Points: 
  • Keros is honored to have the opportunity to bring awareness of FOP to a wider audience.
  • We sincerely thank both Nancy and Professor Keen for participating in the segment and bringing a voice to the challenges that all patients with FOP face daily.
  • "We were happy to have Keros and IFOPA involved in bringing about this important segment on FOP," says Carri Levy, Creator - Behind the Mystery: Rare and Genetic Series.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.

Fibrodysplasia Ossificans Progressiva (FOP) Pipeline Insights 2020: Clinical Development Scenario, Growth Prospects and Pipeline Landscape - ResearchAndMarkets.com

Retrieved on: 
Friday, July 3, 2020
Pharmaceutical, Health, Clinical trials, Rare diseases, Health, FOP, Fibrodysplasia ossificans progressiva, Branches of biology, Fibrodysplasia, Medicine, International FOP Association, Myositis ossificans

Fibrodysplasia Ossificans Progressiva (FOP) Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Fibrodysplasia Ossificans Progressiva (FOP) market.

Key Points: 
  • Fibrodysplasia Ossificans Progressiva (FOP) Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Fibrodysplasia Ossificans Progressiva (FOP) market.
  • A detailed picture of the Fibrodysplasia Ossificans Progressiva (FOP) pipeline landscape is provided, which includes the disease overview and Fibrodysplasia Ossificans Progressiva (FOP) treatment guidelines.
  • The assessment part of the report embraces in-depth Fibrodysplasia Ossificans Progressiva (FOP) commercial assessment and clinical assessment of the Fibrodysplasia Ossificans Progressiva (FOP) pipeline products from the pre-clinical developmental phase to the marketed phase.
  • The Fibrodysplasia Ossificans Progressiva (FOP) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Fibrodysplasia Ossificans Progressiva (FOP) across the complete product development cycle, including all clinical and nonclinical stages.